N
CORV

Natixis’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Natixis’s Portfolio CORV Stock Details CORV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-12,300
Closed -$77K – 615
2013
Q4 		$77K Buy
+12,300
New +$64.5K ﹤0.01% 513

Other funds holding CORV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FIG
Fortress Investment Group New York $531M AUM 12.95% 1-Year Est. Return
ACM
Alistair Capital Management Dallas, Texas $391M AUM 5.89% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return

Natixis's CORV Position: Q1 2014 in Review

Natixis sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q1 2014, closing a stake of 12,300 shares — an estimated $77K sold.

Natixis first reported a position in CORV in Q4 2013 and held it in 1 quarter. The position peaked at $77K in Q4 2013. 30 funds tracked by Wall St. Rank hold CORV as of Q1 2014.

  • Natixis reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q1 2014 after selling out during the quarter.
  • Natixis sold 12,300 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q1 2014, an estimated $77K.
  • Natixis first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q4 2013 and held it in 1 quarter.
  • Natixis's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $77K in Q4 2013.
  • 30 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q1 2014.

Based on Natixis's 13F filing for Q1 2014, filed 14 May 2014.